Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

Search

Reset Filter
You have a filtered search result

203 search results for ‘*’

Business & Regulation Business Practice

What’s in a Name?

| Maryam Mahdi

That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

Discovery & Development Drug Discovery

Down with the Resistance

Are all antibiotics doomed to eventual impotence? New work from Oxford could change the game by defeating resistance itself.

Business & Regulation Business Practice

Time Will Always Tell

| Maryam Mahdi

Sitting Down With Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene.

Discovery & Development Drug Discovery

A Little Byte of Life

Thorben Seeger wants to democratize the data held by the world’s leading genomic institutions. But what exactly does he mean by “democratize”?

Discovery & Development Business Practice

“We Want to Return to the Lab”: How the Russian Invasion Has Disrupted Drug Discovery in Ukraine

| Angus Stewart

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.

Discovery & Development Digital Technologies

A Pain-Free Reality

| Stephanie Sutton

Enter the world of immersive therapeutics – where VR is being explored as an alternative to traditional medicines for pain.

Manufacture Ingredients

Moving Away From “Quality by Fear”: Part II

| Stephanie Sutton

Welcome to Part II of our roundtable discussion about a pilot program in the US for novel excipients featuring experts from IPEC-Americas.

Discovery & Development Drug Delivery

Prodrugs Assemble

Work by an international team in Japan has found a new and effective way to attack cancer inside the body.

Manufacture Dosage Forms

Opiate Alternative

As the fires of the American opioid crisis continue to burn, can new painkillers step in?

Manufacture Ingredients

Moving Away From “Quality by Fear”: Part I

| Stephanie Sutton

Read our roundtable discussion about a pilot program in the US for novel excipients featuring experts from IPEC-Americas.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register